Prevencio Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
2
Prevencio General Information
Description
Developer of multi-proteomic biomarkers designed to transform blood tests for cardiovascular disease. The company's biomarkers employ artificial intelligence to interrogate well-characterized clinical data sets to produce novel, multi-protein, algorithmically-scored tests, enabling clinicians to assess pre-drug or post-drug effects on a composite of heart attack, stroke and cardiac death.
Contact Information
Website
www.prevenciomed.comCorporate Office
- 6424 Lake Washington Boulevard North East
- Suite 13
- Kirkland, WA 98033
- United States
Corporate Office
- 6424 Lake Washington Boulevard North East
- Suite 13
- Kirkland, WA 98033
- United States
Prevencio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | 29-May-2024 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B1) | 16-Mar-2022 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-Oct-2019 | Completed | Clinical Trials - General | |||
| 2. Later Stage VC (Series B) | 30-Jun-2016 | $4.8M | $6.8M | Completed | Clinical Trials - General | |
| 1. Later Stage VC (Series A) | 30-Dec-2013 | $2M | $2M | Completed | Clinical Trials - General |
Prevencio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-0 | ||||||||
| Series B1 | ||||||||
| Series B | 5,562,744 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 21.76% |
| Series A | 3,578,826 | $0.000100 | 8% | $0.9 | $0.9 | 1x | $0.9 | 14% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Prevencio Comparisons
Industry
Financing
Details
Prevencio Competitors (7)
One of Prevencio’s 7 competitors is Datar Cancer Genetics, a Venture Capital-Backed company based in Nashik, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Datar Cancer Genetics | Venture Capital-Backed | Nashik, India | ||||
| Natera | Formerly VC-backed | Austin, TX | ||||
| Foundation Medicine | Formerly VC-backed | Boston, MA | ||||
| XCyton | Venture Capital-Backed | Bangalore, India | ||||
| Positive Biosciences | Corporation | Mumbai, India |
Prevencio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Prevencio Patents
Prevencio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220178946-A1 | Prognostic and diagnostic methods for risk of acute kidney injury | Inactive | 02-Nov-2018 | ||
| US-20260029410-A1 | Prognostic and diagnostic methods for risk of acute kidney injury | Pending | 02-Nov-2018 | ||
| WO-2020092909-A1 | Prognostic and diagnostic methods for risk of acute kidney injury | Inactive | 02-Nov-2018 | ||
| CA-3081752-A1 | Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes | Pending | 02-Nov-2017 | ||
| EP-3704491-A1 | Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes | Inactive | 02-Nov-2017 | G01N33/6893 |
Prevencio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Prevencio Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| MedTech Innovator | Accelerator/Incubator | |||
| G4A | Accelerator/Incubator | Minority |
Prevencio FAQs
-
When was Prevencio founded?
Prevencio was founded in 2006.
-
Where is Prevencio headquartered?
Prevencio is headquartered in Kirkland, WA.
-
What is the size of Prevencio?
Prevencio has 10 total employees.
-
What industry is Prevencio in?
Prevencio’s primary industry is Discovery Tools (Healthcare).
-
Is Prevencio a private or public company?
Prevencio is a Private company.
-
What is Prevencio’s current revenue?
The current revenue for Prevencio is .
-
How much funding has Prevencio raised over time?
Prevencio has raised $15.2M.
-
Who are Prevencio’s investors?
MedTech Innovator and G4A have invested in Prevencio.
-
Who are Prevencio’s competitors?
Datar Cancer Genetics, Natera, Foundation Medicine, XCyton, and Positive Biosciences are some of the 7 competitors of Prevencio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
